Becton, Dickinson and Company $BDX Shares Sold by Wellington Management Group LLP

Key Points

• Wellington Management Group LLP significantly reduced its stake in Becton, Dickinson and Company by 89.6%, selling 959,347 shares and now holding 111,058 shares valued at approximately $25.4 million.
• Becton, Dickinson reported an EPS of $3.68 for the most recent quarter, exceeding analyst expectations and increasing revenues by 10.4% year-over-year.
• The company also announced a quarterly dividend of $1.04, representing an annual yield of 2.1%, with a dividend payout ratio of 74.82%.

Wellington Management Group LLP lessened its holdings in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 89.6% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 111,058 shares of the medical instruments supplier's stock after selling 959,347 shares during the period. Wellington Management Group LLP's holdings in Becton, Dickinson and Company were worth $25,439,000 at the end of the most recent reporting period.

Several other institutional investors also recently added to or reduced their stakes in BDX. GQG Partners LLC acquired a new position in Becton, Dickinson and Company during the first quarter worth approximately $689,833,000. Vanguard Group Inc. increased its position in Becton, Dickinson and Company by 4.7% during the first quarter. Vanguard Group Inc. now owns 28,002,802 shares of the medical instruments supplier's stock worth $6,414,322,000 after buying an additional 1,259,750 shares during the period. Nuveen LLC acquired a new position in Becton, Dickinson and Company during the first quarter worth approximately $211,097,000. GAMMA Investing LLC increased its position in Becton, Dickinson and Company by 29,654.0% during the first quarter. GAMMA Investing LLC now owns 744,445 shares of the medical instruments supplier's stock worth $170,523,000 after buying an additional 741,943 shares during the period. Finally, Massachusetts Financial Services Co. MA increased its position in Becton, Dickinson and Company by 10.8% during the first quarter. Massachusetts Financial Services Co. MA now owns 6,843,856 shares of the medical instruments supplier's stock worth $1,567,654,000 after buying an additional 667,957 shares during the period. Institutional investors and hedge funds own 86.97% of the company's stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. Stifel Nicolaus dropped their target price on Becton, Dickinson and Company from $280.00 to $224.00 and set a "buy" rating on the stock in a report on Friday, May 2nd. Morgan Stanley boosted their target price on Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an "overweight" rating in a report on Monday, August 11th. The Goldman Sachs Group lowered Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $192.00 target price on the stock. in a report on Friday, May 2nd. Barclays dropped their target price on Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating on the stock in a report on Tuesday, June 3rd. Finally, Wall Street Zen raised Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. Four analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $211.44.

Becton, Dickinson and Company Price Performance

BDX traded up $1.59 during trading on Friday, reaching $192.84. 1,329,461 shares of the stock were exchanged, compared to its average volume of 2,590,658. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62. Becton, Dickinson and Company has a 1 year low of $163.33 and a 1 year high of $251.99. The business's 50 day moving average price is $183.07 and its two-hundred day moving average price is $194.27. The company has a market capitalization of $55.27 billion, a price-to-earnings ratio of 34.68, a P/E/G ratio of 1.43 and a beta of 0.20.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.40 by $0.28. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The business had revenue of $5.51 billion for the quarter, compared to the consensus estimate of $5.50 billion. During the same period in the prior year, the business earned $3.50 earnings per share. The business's revenue was up 10.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. As a group, equities research analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th will be given a $1.04 dividend. This represents a $4.16 annualized dividend and a dividend yield of 2.2%. The ex-dividend date is Monday, September 8th. Becton, Dickinson and Company's dividend payout ratio is currently 74.82%.

Insider Activity

In related news, Director Claire Fraser sold 863 shares of the company's stock in a transaction on Friday, August 8th. The stock was sold at an average price of $192.30, for a total value of $165,954.90. Following the completion of the transaction, the director directly owned 23,143 shares in the company, valued at approximately $4,450,398.90. This represents a 3.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Michael David Garrison sold 1,185 shares of the company's stock in a transaction dated Friday, July 18th. The stock was sold at an average price of $180.29, for a total value of $213,643.65. Following the sale, the executive vice president owned 4,887 shares of the company's stock, valued at $881,077.23. This represents a 19.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 3,214 shares of company stock worth $579,206 over the last three months. 0.36% of the stock is currently owned by corporate insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.